Targeted kinase inhibitor Entrectinib

Entrectinib (Entrectinib) is a targeted drug targeting specific gene fusions. It is a multi-target inhibitor that mainly acts on some specific fusion proteins, such asROS1, NTRK and ALK. These fusion proteins appear in some tumors and cause tumors to grow and spread by precisely targeting abnormal proteins within tumor cells. Entrectinib inhibits the activity of these fusion proteins, thereby interfering with the signaling pathways in tumor cells and achieving the purpose of inhibiting tumor growth. Targeted drugs are different from traditional chemotherapy drugs in that they act more selectively on tumor cells and reduce their impact on normal cells, thereby reducing side effects to a certain extent.